<DOC>
	<DOCNO>NCT02611518</DOCNO>
	<brief_summary>The purpose study look take JNJ-54861911 every day effect amount rosuvastatin metformin blood take single dose either one .</brief_summary>
	<brief_title>A Pharmacokinetic Interaction Study Between JNJ-54861911 Transporter Substrates Rosuvastatin Metformin Healthy Participants</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , single-center , fixed sequence , 2-panel study total 32 healthy adult participant ( 16 participant per panel ) . The study consist 3 phase : Screening Phase approximately 3 week ( Days -22 -2 ) , Open-Label Treatment Phase consist single 19 day Treatment Period Panel 1 ( Days -1 18 ) single 18 day Treatment Period Panel 2 ( Days -1 17 ) Follow-up Phase 5 7 day . In Panel 1 , participant administer single oral dose 10 milligram ( mg ) rosuvastatin Day 1 Day 14 . Participants receive JNJ-54861911 dose 25 mg daily Day 8 Day 17 . In Panel 2 , participant administer single oral dose 500 mg metformin Day 1 Day 14 . Participants receive JNJ-54861911 dose 25 mg daily Day 8 Day 16 . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Signed informed consent document indicate understand purpose procedure require study willing participate study Willing adhere prohibition restriction specify protocol All woman must negative serum pregnancy test Screening Day minus ( ) 1 Treatment Period If woman must childbearing potential : postmenopausal ( great [ &gt; ] 45 year age amenorrhea least 12 month , age amenorrhea least 6 month serum follicle stimulate hormone { FSH } level &gt; 40 International Units /Litre [ IU/L ] ) ; document permanently sterilize ( example , tubal occlusion , hysterectomy , bilateral salpingectomy ) ; otherwise incapable pregnancy If woman , must agree donate egg ( ovum , oocytes ) purpose assist reproduction study 3 month receive last dose study drug Nonsmoker Known allergy rosuvastatin , metformin , JNJ54861911 heparin history heparin induce thrombocytopenia History current clinically significant medical illness clinically significant 12lead electrocardiogram ( ECG ) abnormality Donated blood blood product substantial loss blood ( 500 milliliter [ mL ] ) within 3 month first administration study drug intention donate blood blood product study Received experimental drug use experimental medical device within 1 month within period le 10 time drug 's halflife , whichever longer , first dose study drug schedule Unable swallow solid , oral dosage form whole aid water If man , plan father child enrol study 3 month receive last dose study drug Vulnerable participant Participants enrol exposure radiologic magnetic resonance study involve use intravascular contrast material ( example , compute tomography [ CT ] scan intravascular contrast material ) , within 48 hour prior Screening duration study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>JNJ-54861911</keyword>
	<keyword>Rosuvastatin</keyword>
	<keyword>Metformin</keyword>
</DOC>